CHICAGO — The Food and Drug Administration has approved a new pocket-sized packet option for a testosterone-replacement therapy made by AbbVie, the drug maker said Friday. AbbVie announced the ...
In a multicenter, randomized, double-blind, placebo-controlled, noninferiority trial, we enrolled 5246 men 45 to 80 years of age who had preexisting or a high risk of cardiovascular disease and who ...
Please provide your email address to receive an email when new articles are posted on . The FDA stated a warning about adverse CV outcomes with testosterone therapy can be removed based on data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback